)
Anjali Singh covers the automobile and pharmaceutical sectors, focusing on trends, policy developments, regulatory changes, industry expectations, corporate results among others. A postgraduate in communication journalism, she has a strong inclination towards data-driven reporting and enjoys breaking down complex topics to make them interesting and relevant for readers.
Anjali Singh covers the automobile and pharmaceutical sectors, focusing on trends, policy developments, regulatory changes, industry expectations, corporate results among others. A postgraduate in communication journalism, she has a strong inclination towards data-driven reporting and enjoys breaking down complex topics to make them interesting and relevant for readers.
Strained Centre-state relations had long made investors wary, a sentiment reinforced by Trinamool leader Mamata Banerjee's rise on the back of a land agitation in Singur and Nandigram
The company posted a net loss of ₹100.2 crore in Q4 FY26, compared with a loss of ₹234.3 crore in the year-ago period
Aggressive discounting persists in the EV market as automakers juggle inventory, competition, and evolving buyer expectations
Strong growth in hospitals, clinics and labs drives earnings; margins expand on operating leverage and cost discipline across key regional clusters
Castrol India is relying on price hikes and rural expansion to offset rising costs, while sustaining growth through steady demand and market share gains across segments
Piramal Pharma expects a recovery in FY27 with mid-teens revenue growth and improved margins, supported by CDMO rebound, stronger order inflows, and global supply chain shifts
Tyre maker posts strong earnings on international growth and improved mix, but flags near-term margin pressure from rising raw material costs
Castrol India posted steady Q1 FY26 results with higher revenue and profit growth, supported by robust rural and industrial demand, even as it flagged currency volatility & raw material cost pressures
Industry stakeholders believe the move could provide a meaningful boost to India's auto exports, particularly at a time when companies are looking to diversify markets and scale global operations
Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges
Eight Indian auto brands feature in global top 100, with Mahindra leading at 25th as strong SUV demand, EV push and global expansion drive rising brand value
IKS Health's proposed TruBridge acquisition aims to integrate EHR and workflow tools, drive cost efficiencies, and unlock AI-led gains in the US healthcare market
Classic Legends shifts export focus to Europe and other markets while turning profitable, navigating US uncertainty and supply chain disruptions
Tesla is prioritising charging, service and ownership ecosystem in India before scaling volumes, aiming to overcome structural barriers in the nascent EV market
The report also points to a shift towards hybrid healthcare models, where patients prefer AI-assisted human care rather than relying solely on doctors or machines
Industry experts and consumer groups highlight inflated pricing and lack of transparency in healthcare MRPs, urging regulatory intervention for fair pricing
Drugmaker highlights patient safety risks and pledges cooperation with authorities after seizure of suspected counterfeit Mounjaro products in Gurugram
Passenger vehicle demand outstrips supply in FY26, tightening inventories and extending wait times as automakers struggle to match strong retail momentum
Currently, more than 95 per cent of Rubicon's revenue comes from the United States (US), where the company has built a generics and specialty portfolio
India's export sector has held up well despite a year marked by geopolitical tensions, tariff volatility, said SBI's Ghosh